Abstract: Some embodiments of the present invention relate to methods and compositions for assessing the absence, presence, progression, or stage of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided.

Abstract: Some embodiments of the present invention relate to methods and compositions for treating cancer. More embodiments include methods and compositions for modulating the activity of the Hedgehog pathway.

Abstract: A wound sealing fluid delivery apparatus and method includes a surface seal. A catheter with a first end and a second end is provided such that the catheter passes through the surface seal. An infusion port is connected with the first end of the catheter and an expandable internal seal is connected with the catheter at the second end.

Abstract: Some embodiments of the present invention relate to methods and compositions for assessing the absence, presence, progression, or stage of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided.

Abstract: Embodiments of the present disclosure relate to methods and compositions for the diagnosis and treatment of breast cancer. In some embodiments, the present disclosure relates to the use of Merlin, OPN and particular microRNAs for evaluating the presence of breast cancer in a subject and for identifying therapeutic compounds.

Abstract: The present invention relates to methods and compositions for the diagnosis, prognosis and treatment of neoplastic disorders. Some embodiments include methods, compositions, and kits for the prognosis and treatment of prostate cancer.

Abstract: Some embodiments of the present invention relate to methods and compositions for assessing the absence, presence, progression, or stage of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided.

Abstract: An aqueous ionic absorbent solution is disclosed containing (a) about 15 wt. % to about 80 wt. % of one or more diluents, based on the total weight of the aqueous ionic absorbent solution; and (b) an ionic absorbent containing a cation and an anion comprising an amine moiety.

Abstract: Disclosed herein is a method for improving the total energy demand required to separate carbon dioxide (CO2) from an aqueous ionic absorbent solution in a post-combustion carbon capture process. The method involves (a) contacting a flue gas stream containing CO2 with an aqueous ionic absorbent solution under absorption conditions to absorb at least a portion of the CO2 from the flue gas stream and form a CO2-aqueous ionic absorbent solution stream, wherein the aqueous ionic absorbent solution comprises one or more diluents and an ionic absorbent containing a cation and an anion comprising an amine moiety; and (b) subjecting at least a portion of the CO2-aqueous ionic absorbent solution stream to desorption conditions to form a CO2-rich stream and an aqueous ionic absorbent solution stream having a reduced CO2 content.

Abstract: A process and system for separating CO2 from a flue gas stream is disclosed. The process involves (a) contacting a flue gas stream containing water vapor and CO2 with an ionic absorbent under absorption conditions to absorb at least a portion of the CO2 from the flue gas stream and form a CO2-absorbent complex; wherein the ionic absorbent comprises a cation and an anion comprising an amine moiety; and (b) recovering a gaseous product having a reduced CO2 content.

Abstract: The present invention relates to methods and compositions for diagnosing and treating cancer, such as breast cancer and skin cancer.

Abstract: The present invention is directed to methods for enhanced retroviral delivery of a nucleic acid to a target cell in vitro, ex vivo or in vivo, which involves increasing infectivity of a retrovirus carrying a transgene of interest to a target cell. In one particular aspect the invention relates to a method for increasing retroviral infectivity of target cells comprising culturing packaging cells transfected with retroviral vector containing a transgene of interest in medium containing a glucocorticoid receptor agonist or analog or derivative thereof present in the medium in an amount effective to increase titer of propagated retrovirus; and subsequently culturing a target cell in medium comprising the propagated retrovirus from a) and a glucocorticoid receptor antagonist or analog or derivative thereof present in the medium in an amount effective to increase target cell sensitivity to infection by the propagated retrovirus.

Abstract: The present invention is directed to compositions and methods of preserving viability of islets of Langerhans for transplantation, and treating various diseases and other abnormal or pathological conditions, including inflammatory bowel disease, ischemic heart disease, acute lung injury, acute respiratory distress syndrome and radiation-induced brain injury, with DNA repair enzymes that are directed to the mitochondria.

Abstract: One aspect of the present invention relates to ionic liquids comprising a pendant Bronsted-acidic group, e.g., a sulfonic acid group. Another aspect of the present invention relates to the use of an ionic liquid comprising a pendant Bronsted-acidic group to catalyze a Bronsted-acid-catalyzed chemical reaction. A third aspect of the present invention relates to ionic liquids comprising a pendant nucleophilic group, e.g., an amine. Still another aspect of the present invention relates to the use of an ionic liquid comprising a pendant nucleophilic group to catalyze a nucleophile-assisted chemical reaction. A fifth aspect of the present invention relates to the use of an ionic liquid comprising a pendant nucleophilic group to remove a gaseous impurity, e.g., carbon dioxide, from a gas, e.g., sour natural gas.

Abstract: The present invention relates to a composition, method and kit for treating cancer. The treatment comprises administering a pre-sensitizing agent to a tumor or subject, and administering a cancer therapy to the tumor cells or subject. The pre-sensitizing agent increases or induces the apoptosis of the tumor cells, as compared to the rate of apoptosis of tumor cells that have not been pre-sensitized prior to receiving the cancer therapy. In another aspect, the invention relates to a kit comprising a pre-sensitizing agent and a cancer therapy.

Abstract: The present invention relates to novel ionic liquids comprising a docusate, docusate variant, or other sulfonate anion. The ionic liquids may be conveniently made via, for example, metathesis. The ionic liquids are often hydrophobic and useful in many hydrocarbon compositions, polymer compositions, and in supercritical carbon dioxide applications. The ionic liquids are capable of hindering static electricity buildup in the hydrocarbon compositions and can therefore minimize flammability and/or explosiveness.

Abstract: One aspect of the present invention relates to ionic liquids comprising a pendant Bronsted-acidic group, e.g., a sulfonic acid group. Another aspect of the present invention relates to the use of an ionic liquid comprising a pendant Bronsted-acidic group to catalyze a Bronsted-acid-catalyzed chemical reaction. A third aspect of the present invention relates to ionic liquids comprising a pendant nucleophilic group, e.g., an amine. Still another aspect of the present invention relates to the use of an ionic liquid comprising a pendant nucleophilic group to catalyze a nucleophile-assisted chemical reaction. A fifth aspect of the present invention relates to the use of an ionic liquid comprising a pendant nucleophilic group to remove a gaseous impurity, e.g., carbon dioxide, from a gas, e.g., sour natural gas.

Abstract: A plasmid, viral or linear DNA molecule containing a nucleic acid sequence derived from the promoter region of the hCol1?2 gene, which is selectively transported into the nuclei of cells in the osteoblast lineage. The sequence can be used independently as a nuclear entry sequence only, and/or as a nuclear entry sequence without regard to position, in a vector or linear DNA that directs gene expression and nuclear entry. The disclosure further includes a chimeric DNA sequence derived by the addition of osteoblast-specific enhancer sequences to the nuclear entry sequence/promoter sequence, to increase osteoblast-specific expression while retaining osteoblast-specific nuclear import. An enhancer sequence is derived from the promoter region of the human Core Binding Factor alpha 1 (Cbfa1/Runx2) gene. The Cbfa1/Runx2 promoter can be added to the sequence derived from, or alternatively, comprising the promoter region of the hCol1?2 gene. Also provided are methods of use of the novel sequences.

Abstract: One aspect of the present invention relates to ionic liquids comprising a pendant Bronsted-acidic group, e.g., a sulfonic acid group. Another aspect of the present invention relates to the use of an ionic liquid comprising a pendant Bronsted-acidic group to catalyze a Bronsted-acid-catalyzed chemical reaction. A third aspect of the present invention relates to ionic liquids comprising a pendant nucleophilic group, e.g., an amine. Still another aspect of the present invention relates to the use of an ionic liquid comprising a pendant nucleophilic group to catalyze a nucleophile-assisted chemical reaction. A fifth aspect of the present invention relates to the use of an ionic liquid comprising a pendant nucleophilic group to remove a gaseous impurity, e.g., carbon dioxide, from a gas, e.g., sour natural gas.

Abstract: One aspect of the present invention relates to amine-functionalized task-specific ionic liquids (TSILs). In certain embodiments, the ionic liquids of the invention comprise beta-hydroxy amines, aryl amines or tertiary amines. The TSILs may be used for gas capture, capitalizing on their non-volatile nature. In certain embodiments, the captured gas is selected from the group consisting of CO2, SO2, CS2, and NO2. Another aspect of the present invention relates to a library of CO2-philic salts, which library facilitates reactive gas separation. In certain embodiments, the CO2-philic salts are CO2-reactive TSILs. In certain embodiments, the CO2-philic salts are resinous or plastic in nature.